sponsored
PatientsVille.com Logo

PatientsVille

Concomitant Medical Research Studies

Up-to-date List of Concomitant Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Concomitant Medical Research Studies

Rank Status Study
1 Recruiting Efficacy of 10-day Concomitant Regimen Versus High Dose Dual Therapy in Anti-Helicobacter Pylori Rescue Therapy
Condition: Helicobacter Pylori Infection
Interventions: Drug: high dose dual therapy;   Drug: Concomitant therapy
Outcome Measures: to compare the efficacy of 10-day Concomitant regimen versus high dose dual therapy used as atni-Helicobacter pylori rescue therapy;   to compare the adverse effects and patient adherence of 10-day Concomitant regimen versus high dose dual therapy used as atni-Helicobacter pylori rescue therapy
2 Recruiting Concomitant Therapy of H. Pylori
Condition: Gastritis, Gastric Ulcer, and Duodenal Ulcer
Intervention: Drug: amoxicillin, clarithromycin, metronidazole, rabeprazole
Outcome Measure: Evaluation of the efficacy of Concomitant therapy for eradication of Helicobacter pylori
3 Recruiting RCT: Triple vs Sequential vs Concomitant Therapy H Pylori
Condition: Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
Interventions: Drug: 10 day triple therapy;   Drug: 10 day sequential therapy;   Drug: 10 day Concomitant therapy
Outcome Measure: H pylori eradication rate
4 Recruiting Comparison of the Eradications Rates of Sequential Therapy Versus Concomitant Therapy
Condition: Helicobacter Pylori Infection
Interventions: Drug: pantoprazole, amoxicillin, clarithromycin, metronidazole;   Drug: pantoprazole, amoxicillin, clarithromycin, metronidzole
Outcome Measure: Comparison of the eradications rates of sequential therapy versus Concomitant therapy of treatment of Helicobacter pylori infection in Korea.
5 Recruiting Randomised Study of Concomitant Radiochemotherapy in Non-small Cell Lung Cancer
Condition: Non-small Cell Lung Carcinoma
Interventions: Drug: Concomitant Radiochemotherapy - Radiotherapy 66 Gy, Cisplatin, and Docetaxel;   Drug: Concomitant Chemoradiotherapy - Radiotherapy 66 Gy, Cisplatin, and Docetaxel
Outcome Measures: Survival;   Response rate;   Toxicity;   Local control rate
6 Recruiting Trial Comparing Two Protocols of re Irradiation in an Irradiated Area for Carcinoma of the Upper Aerodigestive Tract
Condition: Squamous Cell Carcinoma
Interventions: Radiation: single-fraction radiotherapy with Concomitant 5FU and Hydrea;   Radiation: hyperfractionated radiotherapy with Concomitant Cetuximab
Outcome Measures: Acute toxicity requiring an interruption of radiotherapy for more than 2 weeks;   Overall survival at 3 years and loco-regional control at 3 years
7 Unknown  Concomitant Chemoradiation in Advanced Stage Carcinoma Cervix
Condition: Cancer of Cervix
Intervention:
Outcome Measures: To evaluate the single agent Concomitant chemotherapy (Cisplatin) in Stage IIIB carcinoma cervix;   To compare the disease free survivals.;   To compare the normal tissue toxicities (Acute & Late) of standard radiation therapy with Concomitant chemo-radiation.;   To compare the overall survivals;   To compare the distant metastasis rates;   To compare the quality of life in both the groups
8 Recruiting Diagnostic Performance of 18F-FDG-PET and Diffusion-weighted MRI in the Assessment of Stage IB to IIB2 Cervical Squamous-cell Carcinoma Response to Concomitant Radiochemotherapy and Brachytherapy
Condition: Squamous-cell Cervical Carcinoma Stage IB2 to IIB Without Spread to Lymph Nodes or Metastasis
Intervention: Device: 18F-FDG-PET
Outcome Measures: Sensitivity of 18F-FDG-PET in the assessment of stage IB to IIB2 cervical squamous-cell carcinoma response to Concomitant radiochemotherapy and brachytherapy;   Specificity and likehood ratios of 18F-FDG-PET in the assessment of stage IB to IIB2 cervical squamous-cell carcinoma response to Concomitant radiochemotherapy and brachytherapy;   Diagnostic performances of diffusion-wheighed MRI in the assessment of stage IB to IIB2 cervical squamous-cell carcinoma response to Concomitant radiochemotherapy and brachytherapy
9 Unknown  Concomitant Chemo-radiotherapy Plus VIDL Chemotherapy in NK/T-cell Lymphoma
Condition: Stage I/II Extranodal NK/T-cell Lymphoma
Intervention: Other: Concomitant chemo-radiotherapy followed by VIDL chemotherapy with risk-based application of autologous stem cell transplantation
Outcome Measures: Compete response rate;   Overall response rate, survival, toxicity
10 Unknown  A Phase II Study Of Gliadel, Concomitant Temozolomide And Radiation, Followed By Dose Dense Therapy With Temozolomide Plus Bevacizumab For Newly Diagnosed Malignant High Grade Glioma
Condition: Glioma
Intervention: Drug: Temozolomide and Bevacizumab
Outcome Measure: Safety and efficacy of Concomitant limited field radiation therapy and temozolomide, followed by dose dense temozolomide and bevacizumab in subjects undergoing initial surgery for newly-diagnosed high grade glioma.
11 Recruiting Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-erbitux
Condition: HNSCC
Interventions: Drug: cetuximab;   Drug: Carboplatin, 5FU Concomitant;   Radiation: Radiotherapy
Outcome Measures: Progression free survival;   Loco-regional control
12 Unknown  Concomitant Tracheostomy and Lung Resection
Condition: Lung Cancer
Intervention: Procedure: Tracheostomy
Outcome Measures: number of mechanical ventilation days after operation until discharge;   60 days mortality rate;   ICU length of stay;   hospital length of stay;   cumulative incidence of postoperative respiratory complications defined as pneumonia, re-ventilation, atelectasis needing fiberbronchoscopy, non cardiogenic pulmonary edema, air leakage >7 days, broncho-pleural fistula, pulmonary embolism, empyema;   cumulative incidence of postoperative cardiac complications defined as arrythmia needed treatment, cardiac failure needing inotrop drug, acute coronary stroke;   laryngeal and tracheal complications;   general complications
13 Recruiting Safety Study Investigating if Concomitant Injections of C-Tb and 2 T.U Tuberculin Affect Induration Responses
Condition: Tuberculosis
Interventions: Biological: C-Tb;   Biological: Tuberculin PPD RT 23 SSI;   Biological: C-Tb / Tuberculin PPD RT 23 SSI
Outcome Measures: To compare the size of induration of C-Tb and PPD RT 23 if injected alone or Concomitantly in Tuberculosis infected patients (HIV positives and HIV negatives);   To assess if Concomitant injections of C-Tb and PPD RT 23 influence the tests abilities to identify positive results of Tuberculosis in Tuberculosis infected patients;   To compare the C-Tb test's ability to identify positive results in Tuberculosis infected patients with the in vitro QuantiFERON®TB Gold In Tube assay in blood collected immediately before application of the C-Tb skin test;   To compare the C-Tb test's ability to identify positive results in Tuberculosis infected patients with the PPD RT 23 test;   To assess the safety of C-Tb skin test by investigating laboratory safety parameters and assessing all adverse events (local and systemic) occurring within 28 days after administration of the C-Tb and/or PPD RT 23 tests
14 Recruiting Reverse Shoulder Arthroplasty With or Without Concomitant Latissimus and Teres Major Transfer for Shoulder Pseudoparalysis With Teres Minor Dysfunction
Condition: Osteoarthritis of the Shoulder
Interventions: Procedure: Transfer group;   Procedure: Control group
Outcome Measures: ADLER Score;   DASH Score;   ASES score;   SF-12 Score;   Range of Motion;   X-Ray Measurements
15 Not yet recruiting Gallstones and Concomitant Gastric Helicobacter Pylori Infection
Condition: Cholelithiasis
Intervention:
Outcome Measure: Gallstones and Concomitant H.Pylori infection of the gastric mucosa
16 Unknown  Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular Carcinoma
Conditions: Chronic Hepatitis C;   Neoplasms
Intervention: Drug: pegylated interferon alpha 2a and plus ribavirin
Outcome Measures: Efficacy - Sustained virological response (SVR), HCV RNA seronegative by PCR throughout 24-week off-treatment period.;   Rapid virologic response (RVR), HCV RNA seronegative by PCR at week 4.;   Early virological response (EVR), by PCR-negative or at least 2 logs decline from baseline of serum HCV RNA at 12 weeks of treatment.;   Safety - adverse event rate and profile
17 Unknown  Feasibility of Cetuximab Associated With Concomitant Radio-Chemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer
Condition: Non-Small-Cell Lung Carcinoma
Interventions: Drug: cisplatin, vinorlebine, cetuximab;   Drug: cisplatine, etoposide, cetuximab
Outcome Measure: rate of patients presenting at least one toxicity grade≥3 (excepted hematological toxicity and nausea-vomiting)
18 Recruiting Hypofractionation With Simultaneous Integrated Boost for Early Breast Cancer
Condition: Breast Cancer After Breast Conserving Surgery Indicating Postoperative Radiotherapy With Boost
Intervention: Radiation: Hypofractionation with simultaneous integrated boost
Outcome Measures: Acute Toxicity;   Feasibility;   Toxicity;   Quality of life;   Performance
19 Unknown  Rabeprazole Based Sequential-Concommitant Hybrid Therapies for H. Pylori Infections
Condition: Helicobacter Pylori Infection
Interventions: Drug: RA5-RACM7;   Drug: RA3-RACM7;   Drug: RA7-RACM7
Outcome Measure: Eradication rate
20 Recruiting Intensity-Modulated Scanning Beam Proton Therapy (IMPT) With Simultaneous Integrated Boost (SIB)
Condition: Lung Cancer
Interventions: Radiation: IMPT + SIB + Chemotherapy;   Behavioral: Questionnaire;   Radiation: IMRT + SIB + Chemotherapy
Outcome Measures: Maximum Tolerated Dose (MTD);   Progression-Free Survival

These studies may lead to new treatments and are adding insight into Concomitant etiology and treatment.

A major focus of Concomitant research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Concomitant